PCI Biotech announced that it has received clearance by the United States Food and Drug Administration (FDA) to include patients in the USA in its phase II clinical programme for Amphinex. Amphinex is in development as a new local treatment for recurrent head and neck cancer and the phase II program has already been initiated in Europe.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.802 NOK | -0.44% | +0.11% | -13.99% |
1st Jan change | Capi. | |
---|---|---|
-13.99% | 6.28M | |
+20.12% | 126B | |
+25.25% | 119B | |
+25.56% | 27.95B | |
-19.51% | 20.5B | |
-14.36% | 17.12B | |
-15.63% | 16.1B | |
-46.67% | 14.97B | |
+11.89% | 14.84B | |
+57.74% | 14.38B |
- Stock Market
- Equities
- PCIB Stock
- News PCI Biotech Holding ASA
- PCI Biotech Receives Clearance by the United States Food and Drug Administration to Include Patients in the USA in Its Phase II Clinical Programme for Amphinex